New drug combo aims to silence hepatitis b virus
NCT ID NCT05970289
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This study tests whether adding an experimental drug (BRII-835) to standard interferon therapy can better control chronic hepatitis B. About 86 adults on antiviral pills will receive either interferon alone or with different doses of BRII-835. The goal is to see if the combination can clear a key virus marker (HBsAg) and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site 61001
Kingswood, New South Wales, 2747, Australia
-
Investigative Site 61002
Birtinya, Queensland, 4575, Australia
-
Investigative Site 61003
Melbourne, Victoria, 3004, Australia
-
Investigative Site 65001
Singapore, 169856, Singapore
-
Investigative Site 65002
Singapore, 529889, Singapore
-
Investigative Site 66003
Bangkok, 10330, Thailand
-
Investigative Site 66005
Khon Kaen, 40002, Thailand
-
Investigative Site 66006
Nonthaburi, 11000, Thailand
-
Investigative Site 66008
Songkhla, 90110, Thailand
-
Investigative Site 82001
Busan, 49241, South Korea
-
Investigative Site 82002
Chuncheon, Chuncheon-si, 24253, South Korea
-
Investigative Site 82003
Seoul, 6351, South Korea
-
Investigative Site 82004
Daegu, 41566, South Korea
-
Investigative Site 82005
Seoul, 13496, South Korea
-
Investigative Site 82006
Soeul, 05505, South Korea
-
Investigative Site 85201
Hong Kong, HONG KONG, 999077, China
-
Investigative Site 85202
Hong Kong, HONG KONG, 999077, China
-
Investigative Site 86001
Beijing, Beijing Municipality, 100000, China
-
Investigative Site 86001
Beijing, Beijing Municipality, 100050, China
-
Investigative Site 86004
Chongqing, Chongqing Municipality, 400010, China
-
Investigative Site 86006
Guangzhou, Guangdong, 510630, China
-
Investigative Site 86007
Beijing, Beijing Municipality, 100069, China
-
Investigative Site 86008
Changchun, Jilin, 130021, China
-
Investigative Site 86011
Hangzhou, Zhengjiang, 310016, China
-
Investigative Site 86013
Shanghai, Shanghai Municipality, 200025, China
-
Investigative Site 88601
Kaohsiung, Taiwan, 80756, China
-
Investigative Site 88602
Taipei, Taiwan, 10041, China
-
Investigative Site 88603
Taipei, Taiwan, 11217, China
-
nvestigative Site 66007
Chiang Mai, 50200, Thailand
Conditions
Explore the condition pages connected to this study.